BCL2 and acute myeloid leukemia: Venetoclax has a high affinity for the BH3 binding domain of Bcl-2, It inhibits the overexpression of Bcl-2 in acute myeloid leukemia (AML) cells, promoting apoptosis and inhibiting cell proliferation.